Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 366 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: percutaneous coronary intervention Clear all
Terminated Not applicable Interventional Results available

Advanced Reperfusion Strategies for Refractory Cardiac Arrest

NCT03880565
View directory record Official record
Conditions
Cardiac Arrest, Extracorporeal Membrane Oxygenation Complication, Ventricular Fibrillation, Pulseless Ventricular Tachycardia, Out-Of-Hospital Cardiac Arrest
Interventions
Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation, Standard Advanced Cardiac Life Support (ACLS) Resuscitation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 3, 2026, 6:53 PM EDT
Terminated Phase 3 Interventional Results available

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138
View directory record Official record
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
5,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients

NCT00078013
View directory record Official record
Conditions
Myocardial Infarction
Interventions
MCC-135
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography

NCT01848899
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Iodixanol, Ioxaglate, Bivalirudin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 3, 2026, 6:53 PM EDT
Recruiting Early Phase 1 Interventional

Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

NCT05377216
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Stellate Ganglion Block
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Catheter-Based Treatment of Cardiovascular Disease

NCT00380016
View directory record Official record
Conditions
Obstructive Coronary Artery Disease, Obstructive Peripheral Artery Disease, Structural Heart Disease
Interventions
Percutaneous Transluminal Angioplasty
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)

NCT02603835
View directory record Official record
Conditions
Anterior Wall Acute Myocardial Infarction
Interventions
SSO2 Therapy
Device
Lead sponsor
TherOx
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Huntsville, Alabama • La Jolla, California • Danbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting No phase listed Observational

Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions

NCT05187351
View directory record Official record
Conditions
Target Vessel Failure in Saphenous Vein Grafts, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention of the native coronary artery with Synergy
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Detroit, Michigan • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 3, 2026, 6:53 PM EDT
Not listed Not applicable Interventional

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

NCT02594501
View directory record Official record
Conditions
Angina, Stable, Angina, Unstable, Anticoagulants
Interventions
COBRA PzF, Drug Eluting Stent
Device
Lead sponsor
CeloNova BioSciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
22
States / cities
Newark, Delaware • Jacksonville, Florida • Melbourne, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting Not applicable Interventional

OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study

NCT03716102
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
PCI with implantation with DES
Device
Lead sponsor
Svelte Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Scottsdale, Arizona • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention

NCT01996553
View directory record Official record
Conditions
Coronary Angiography, Radial Artery Occlusion
Interventions
Not listed
Lead sponsor
Jesse Brown VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 3, 2026, 6:53 PM EDT
Not listed No phase listed Observational

Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population

NCT01408927
View directory record Official record
Conditions
Increased Drug Resistance
Interventions
Thienopyridine resistance testing, Aspirin resistance testing, Genetic polymorphism assessment
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Angio-Seal Evolution Device Registry

NCT00817349
View directory record Official record
Conditions
Peripheral Vascular Disease, Coronary Artery Disease, Peripheral Artery Disease, Arterial Occlusive Disease, Coronary Heart Disease
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Ypsilanti, Michigan • Camden, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 3, 2026, 6:53 PM EDT
Withdrawn Not applicable Interventional

Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort

NCT01330589
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, St. Johns Wort
Drug
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

NCT02098876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS)
Device
Lead sponsor
Emory University
Other
Eligibility
30 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 3, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

NCT00910299
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

OPTIMIZE PCI: Multicenter Randomized Trial of OCT Compared to IVUS and Angiography to Guide Coronary Stent Implantation

NCT02471586
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary PCI guided by IVUS, Coronary PCI guided by OCT, Coronary PCI guided by Angiography
Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

NCT04668144
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Cangrelor, Prasugrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

The MASS COMM Post-Randomization Phase Cohort Study

NCT02072421
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PCI
Procedure
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
2,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Brockton, Massachusetts • Framingham, Massachusetts • Lawrence, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting Not applicable Interventional

TECTONIC CAD IVL IDE Study

NCT06885177
View directory record Official record
Conditions
Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Interventions
Experimental
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Emergency Medical Services (EMS) Telehealth to Speed STEMI Reperfusion

NCT06945900
View directory record Official record
Conditions
STEMI - ST Elevation Myocardial Infarction
Interventions
Telehealth
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Terminated Phase 4 Interventional

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

NCT00289601
View directory record Official record
Conditions
Angioplasty
Interventions
eptifibatide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2007 · Synced Oct 3, 2026, 6:53 PM EDT